Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
TabrectaⓇ Ⓡ- Met inhibitor
NCT04427072 (CINC280A2301)
Non-small cell lung cancer
Indication
Phase
Phase 3
Patients
90
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Read-out
Milestone(s)
Progression free survival (PFS) per blinded independent review committee
(BIRC) using RECIST v1.1
Arm 1: 400mg of capmatinib tablets administered orally twice daily
Arm 2: Docetaxel 75 mg/m2 by intravenous infusion every 21 days
Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced
or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping
Mutation (METAex14).
Primary 2022
Final: 2024
Publication
TBD
80 Investor Relations | Q3 2022 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation